## RECEIVED CENTRAL FAX CENTER

PTO/S8/21 (09-04) Approved for use through 07/31/2008. OMB 0651-0031 NOV 2 9 2005 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Aut of 1995, no persons Application Number 10/658,241 TRANSMITTAL Filing Date 9/9/03 **FORM** First Named Inventor Alan P. Kozikoswki et al. Art Unit 1626 Examiner Name Robert Shisa (to be used for all correspondence after initial filling) Attorney Docket Number Total Number of Pages in This Submission 105942-53922 **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interterences ~ Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Discialmer Extension of Time Request below): Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Gibbons, Del Deo, Dolan, Griffinger & Vecchione, P.C. Signature Printed name Margaret B. Keiler Date Reg. No. 11/29/06 29,181 CERTIFICATE OF TRANSMISSION/MAILING I heraby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Margaret M. Glijebs Date 11/29/05 Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or ratain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclinidate case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burrent, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commisce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## RECEIVED CENTRAL FAX CENTER

NOV 2 9 2005

Rule 312 Amendment Serial No.: 10/658,241 Gibbons No.: 105942-53915

\_\_\_\_

CERTIFICATE OF MAILING/FAX TRANSMISSION
I hereby certify that this correspondence is being:
\_\_deposited with the United States Post Office in a first class mail
envelope addressed to: Commissioner for Patents, Alexandria, Virginia 22313

XX transmitted via facsimile to the Commissioner for Patents via facsimile number 571-273-8300

Date: November 29, 2005

Name: Margaret M. Glians Signature: Y MARA

dibbons, Del Deo, Dolan, Griffinger & Vecchione, P.C.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan P. Kozikowski et al.

Customer No: 26345

Serial Number: 10/658,241

T.C./A.U.: 1626

Filed: September 9, 2003

Examiner: Robert Shiao

Confirmation No: 4114

For: SYNTHESIS OF DIMERIC, TRIMERIC,

TETRAMERIC, PENTAMERIC, AND HIGHER OLIGOMERIC EPICATECHIN-DERIVED PROCYANIDINS HAVING 4β, 8-INTERFLAVAN LINKAGES AND THEIR USE TO INHIBIT CANCER CELL GROWTH

THROUGH CELL CYCLE ARREST

Attomey Docket: No.:

Gibbons 105942-53915

(formerly 5677-177)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Amendment is submitted to correct errors in Claims 44 and 45.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on Page 5 of this paper.